Feb 62025 Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.
